2. creates new drug forms

3. saves 30% in drug production costsusing PDG technology

4. Market opportunity Customers: pharmaceutical companies - originators and generics: Formulation & Life cycle management department Production department Under pressure: little new products, generic competition and cost pressure by health authorities Market: development and production of tablets ($48.4B, +5%) Targeted market: new tablets ($1.2B) Very big market – 300 new products every year Competition: contract manufacturers (i.e. Patheon, Catalent, Aenova) Production system providers (i.e. Alexanderwerk, Hosakawa, Fitzpatrick) PDG Technology is unique (no base inventions since 20 years) It solves development problems, speed-to-market issues and is cost effective Market share target: 5% in 2015 Market share is only limited by development speed of capacity (investment)

6. Low-cost alternative NOW available

7. Continuous production possible

8. Tablets have unwanted characteristics or don’t hold up

9. Long formulation times: 6-12 months

10. Failure in scale-up (from lab to production)

11. Drug combinations possible

12. Fast dissolution (e.g. 15min.)

13. No stability issues

14. Increasing cost pressure in production (notably Gx); ~$25M prod. cost for $250M in sales

15. No low-cost production process alternative available

16. Continuous production not possible w/ wet granulation

17. Tablets are strong and have specified characteristics

18. Very short formulation time: 4-6 weeks

19. Same system for development and production

20. Drug combinations not possible

21. Onset of drug effect too slow (i.e. 30 min.)

22. Stability problemsor IP: 9 patents pending (all major countries), UK granted, US: Q4 2011

24. Costs saved: $0.5-1M/product

25. Higher reliability of development success

26. 30-40% lower production cost

27. Time saved: 5-12 months

28. Costs saved: $0.2-0.5M/product

29. Patent expiration solution

30. High market acceptance with convenient small tablet

31. Sales level maintained

32. 20-30% lower production cost

33. PDG solution works

34. Production cost saved: $5-7M*/product

35. No registration dossier changes needed (new product with new registration)*= average Gx product sales: $150M, today’s production costs: $22M (15% of sales), 25% saved: $5.6M

37. Trials for 4 companies in preparation

38. 11 clients interested (after first presentations)

40. Develop2 internalproducts

41. File 2 formulationpatents

42. 6 clienttrials

44. File 2 formulationpatents

45. Set-upnew lab & productionsite

46. 6 clienttrials

48. System installation / testing

49. 1 CMO partner

50. 1 distributionpartner

51. 3 internaltrials

53. 1 CMO partnerproviding high containmentenvironment

54. 2 distributionpartners

55. 2 internaltrials

56. 6clienttrials

58. Management Team Steffen Mittwich - CEO 20 yrs of pharmaceutical experience (Pfizer, Novartis, Sanofi-Aventis) Launched Winthrop Generics (start-up) as CEO in Switzerland, grew from $0 to $6M in 2 yrs Group Product Manager at Pfizer – brought Alzheimer’s product to market, grew from $0 to $75M in 3 yrs; responsible for $210M total in revenue from 1998 to 2001 Dr. Rob Lammens - CTO 30 yrs of pharmaceutical development and production experience at Bayer; expert in oral solid dosage forms and dry granulation / roller compaction Improved scale-up from lab to production by creating a new system to determine process upgrade parameters saving approx. $1.3M development cost / product = $20M savings (15 products) Developed leading roller compactor generation as consultant for Gerteis Maschinen Prozessengineering AG Jari Ovaskainen– Main investor & chairman of the board Founded Iobox in 1999, sold for $250M in 2000

60. First contracts estimated for Q3-2011

61. A multitude of further client projects are available and achievable (production capacity for a further 8-10 projects)

62. Atacama seeks bridge funding of 2.85 m€ to secure initial deals (via test developments), broaden platform (high containment) and to cover operational costs

63. Break-even forecast: 2012www.atacamalabs.com